post-traumatic stress disorder News
-
XPhyto Files Patent Application for Library of Novel Psychedelic Compounds
XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report that it has filed a patent application for a significant library of novel psychedelic compounds. Each compound was designed to provide specific alterations in their respective biopharmaceutical properties. The library of compounds can be selected to target ...
-
CanaQuest Launches Mentanine (R) (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC Pink:CANQF) (the "Company" or "CanaQuest"), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine® (cannabidiol "CBD" + IP, Omega-3s, DHA, EPA formula) in ...
-
Canaquest Launches Mentanine (Cannabidiol + IP Formula) in the US via www.canaqueststore.com, Supported by Western University Pre-Clinical Trials Targeting Anxiety, Depression and PTSD
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning, Clinical Stage/Life-Sciences company focused on drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors, today announced its US launch of all-natural Mentanine (cannabidiol “CBD” + IP, Omega-3s, ...
-
CanaQuest Signs Medicinal Cannabis Education Partnership with the Canadian Cannabis Dispute Resolution Centre
Canaquest Medical Corp (OTC Markets: “CANQF”) (the “Company” or “CanaQuest”), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), is pleased to announce its new partnership with the Canadian Cannabis Dispute Resolution Centre (“CCDRC”), a national ...
-
`This emotional life` honored at voice awards ceremony for contribution to mental health understanding
Last night, This Emotional Life, a PBS documentary series that explores social relationships and human happiness, received a 2010 Voice Award at a ceremony sponsored by the Substance Abuse and Mental Health Services Administration (SAMHSA). Co-produced by Paul G. Allen's Vulcan Productions and the NOVA/WGBH Science Unit, This Emotional Life was honored for its respectful and accurate portrayal ...
-
Fundamental Research Corp Initiates Coverage on CanaQuest (CANQF) with Buy Rating and US$0.78 Fair Value Estimate
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced that Fundamental Research Corp (“FRC”), one of the world’s largest independent research houses, has launched coverage ...
-
CanaQuest Medical Corp Appoints Investor Relations and PR Veteran Rob Rinderman as its New Director of Communications
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing health and wellness products combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced that Rob Rinderman has joined CanaQuest as its new Director of Communications. Mr. Rinderman will focus on managing ...
-
CanaQuest Achieves Statistically Significant Reduction of Seizures for Epilepsy Compared to Standard CBD
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced Statistically Significant efficacy results from the Clinical Dose & Efficacy Study ("Study") conducted by Dr. W McIntyre Burnham, ...
-
Flowonix Medical and Cerebral Therapeutics Announce Fifth Implant of First-of-a-Kind Implantable Drug Therapy to Treat Patients with Refractory Epilepsy
Flowonix Medical, Inc. and Cerebral Therapeutics, Inc. announced today the successful implant of the fifth patient in the ADDRESS (Australian Direct Drug Administration for Refractory Epilepsy) trial. The jointly developed therapy features a micro-infusion device which tightly controls drug delivery to a region of the brain for patients with medically refractory epilepsy. "The study ...
-
CanaQuest Files International Mentanine(R) Patent, a Scientific CBD Formulation for Mental Health
Canaquest Medical Corp (OTC PINK:CANQF) (the “Company” or “CanaQuest“), an award-winning Life Science/Pharmaceutical company developing formulations combining cannabinoid molecules with pharmaceutical-grade botanical compounds, today announced the filing of its International Patent, trade named Mentanine, which has demonstrated at least 10-times (10X) the efficacy compared ...
-
Postpartum Mental Health Awareness - Isabel Healthcare
In a recent blog we covered mental health conditions which can occur during pregnancy, but there are also some mental health conditions which can occur after the woman has given birth. The postpartum period is up to a year after giving birth, If a woman has experienced mental ill health in the past, then she is more likely to become mentally unwell during pregnancy or in this postpartum period ...
-
CANAQUEST Announces Award of European Cannabinoid Patent
We believe we can provide a safer alternative to other THC products providing the benefits without the negative psychiatric side effects. Pre-clinical trials have demonstrated the reversal of depression-like and schizophrenia-related symptoms, blockage of memory impairment, hyperactive activity, and gene vulnerability. CanaQuest Medical Corp ("CanaQuest" or the "Company") (OTC:CANQF), a ...
-
CanaQuest and Neeka Health Sign Agreement to Conduct Clinical Studies with Mentanine
Canaquest Medical Corp (OTC:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced the signing of a Master Service Agreement with Neeka Health (“Neeka”) that will encompass multiple clinical studies to evaluate the ...
-
CanaQuest Medical Corp Honored With International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma
CANAQUEST MEDICAL CORP (OTC PINK:CANQF) (the “Company” or “CanaQuest“), a Life Science/Pharmaceutical Company developing health products utilizing cannabinoid molecules and other botanical compounds (pharmaceutical grade), today announced it has been awarded the International CBD Life Science R & D Excellence Award 2020 by Global Health & Pharma, United Kingdom, a ...
-
CanaQuest Awarded Best Global Medical Cannabinoid Development Company 2023 by UK-based Global Health & Pharma for their 8th Annual Healthcare and Pharmaceutical Program
Canaquest Medical Corp (OTC PINK:CANQF) (the "Company" or "CanaQuest"), a clinical-stage life sciences company focused on drug discovery and development of next-generation targeted cannabinoid therapeutics for the central nervous system (CNS), today announced that it has been awarded the Best Global Medical Cannabinoid Development Company 2023, in its eighth annual Healthcare and Pharmaceutical ...
-
NHL Alumni Association partners with CanaQuest and NEEKA Health to Conduct Studies for Anxiety and Quality of Life in former NHL Players
NHL Alumni Association (NHLAA), NEEKA Health Canada("NEEKA"),and CanaQuest Medical Corp ("CanaQuest") are pleased to announce a transformative study partnership that will investigate the efficacy of Mentanine® as a potential treatment to reduce anxiety in former NHL ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you